What Is Methylene Blue?

By Reviv Health Editorial TeamUpdated November 8, 2026

Methylene blue is a synthetic phenothiazine compound, first made as a textile dye in 1876 and later adopted in medicine. In the body it acts as an electron shuttle inside the mitochondria, which is why it's used clinically and studied for cognition and energy. Nobody expects a 19th-century dye to end up in a nootropic stack — but here we are.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before using methylene blue.

Methylene blue has one of the stranger origin stories in medicine. It started as a dye — literally made to color fabric — and somewhere along the way, researchers figured out it does things to human biology that are hard to ignore. An FDA-approved treatment for methemoglobinemia. And now, a growing body of lab and animal research on mitochondrial energy and brain health. That's a weird arc for a dye. But the chemistry behind it actually makes sense once you dig in.

What Is Methylene Blue, Chemically?

Okay, the official name is 3,7-bis(dimethylamino)phenothiazin-5-ium chloride. That's a mouthful. Here's what it means in practice: it's a small, flat, positively charged molecule with a sulfur atom at its center.

In its oxidized form? Deep vivid blue. In its reduced form — called leucomethylene blue — it goes colorless. And that back-and-forth is the whole ballgame. It can accept electrons and go colorless. Then donate those electrons and return to blue. Reversible. Repeatable.

That's not a minor detail. Most compounds do one thing. Methylene blue can act as a reducing agent, an oxidizing agent, a mitochondrial electron carrier, an enzyme inhibitor, and a photosensitizer — sometimes all in the same system, depending on dose and context. As a redox agent, it shuttles electrons between biological molecules in ways that actually matter to cellular function. That versatility is exactly why it keeps showing up in unrelated fields of medicine.

History: From Dye to Medicine

Heinrich Caro synthesized methylene blue in 1876 at BASF. The goal was textile dye — something to replace natural indigo in fabric production. That worked. But within a decade, Paul Ehrlich started using it as a biological stain and noticed something odd: it selectively colored nerve endings and cellular structures in ways that were genuinely useful for microscopic examination. His neuroanatomy work using methylene blue stain became foundational to the discipline.

Then researchers noticed it accumulated in malaria parasites. In 1891, Paul Guttmann and Ehrlich used it to treat two patients with malaria, making methylene blue the first synthetic drug used against the disease (Lu G et al., 2018, BMC Medicine).

That pattern kept repeating. Urological surgery. Psychiatric treatment. Cyanide poisoning management. And eventually, its FDA-approved role as the standard treatment for methemoglobinemia — a rare blood disorder where hemoglobin loses the ability to carry oxygen. Same core chemistry every time. Same electron-shuffling behavior that was just a dye trick in 1876.

What Does Methylene Blue Do for Humans?

The honest answer: it depends heavily on dose.

At clinical intravenous doses — typically 1 to 2 mg/kg — methylene blue acts as a powerful reducing agent in red blood cells. It accepts electrons from NADPH and uses them to convert methemoglobin back to functional hemoglobin, restoring the oxygen-carrying capacity of blood that's been chemically compromised. It usually works within an hour, and it can be life-saving.

At the much smaller amounts taken as a supplement, the effects people are interested in are mitochondrial. In cell and animal studies, methylene blue can bypass damaged sections of the electron transport chain, passing electrons directly to cytochrome c and supporting ATP production (Wen Y et al., 2011, Journal of Biological Chemistry). Neurons are especially energy-hungry, which is why the research focuses on the brain. Whether small daily servings improve focus or memory in healthy people hasn't been shown in trials.

Methylene blue is also a potent inhibitor of monoamine oxidase A, the enzyme that breaks down serotonin (Ramsay RR et al., 2007, British Journal of Pharmacology). That may explain some of its effects on mood, and it's the reason its drug interactions need to be taken seriously.

Methylene Blue as a Biological Stain

Before it was a medicine, methylene blue was a laboratory tool. Still is. Its positive charge gives it strong affinity for negatively charged molecules — DNA, RNA, certain proteins — which makes it excellent for staining cell nuclei and nucleic acids. Standard stuff in microbiology labs.

But it's not just academic. In clinical microbiology, methylene blue stain is used to visualize bacteria in diagnostic smears. In hematology, a modified version stains reticulocytes — immature red blood cells — to assess bone marrow function. In oncology surgery, it's injected near tumors to highlight sentinel lymph node tissue for biopsy. That lymph node mapping helps surgeons determine whether cancer has spread. These aren't experimental. They're routine clinical uses with decades of practice behind them.

The FDA-Approved Use: Methemoglobinemia

Methemoglobinemia is what happens when the iron in hemoglobin gets oxidized from its normal ferrous (Fe²⁺) state to ferric (Fe³⁺) methemoglobin. And methemoglobin can't bind oxygen. As levels rise, patients develop a grayish-blue skin discoloration, shortness of breath, and — above 50 to 70% methemoglobin saturation — life-threatening tissue hypoxia.

Methylene blue reverses it fast. Administered intravenously at 1 to 2 mg/kg, it gets reduced by NADPH (via methemoglobin reductase) to leucomethylene blue, which directly reduces methemoglobin back to functional hemoglobin. That's the mechanism behind FDA approval of injectable methylene blue under the brand name ProvayBlue (FDA ProvayBlue label).

One caveat that cannot be skipped: this mechanism requires G6PD enzyme function. People with G6PD deficiency — glucose-6-phosphate dehydrogenase deficiency — don't generate enough NADPH in red blood cells. In those individuals, methylene blue can't complete its reduction cycle and may instead trigger hemolytic anemia. G6PD status needs to be checked before use, especially for people of African, Mediterranean, Middle Eastern, or Southeast Asian descent, where this condition is more common.

Off-Label Uses: The Supplement Frontier

Here's where most people outside of emergency medicine actually encounter methylene blue: the off-label use territory. Cognitive enhancement. Mood support. Energy optimization. Anti-aging.

None of these uses are FDA-approved. Here is what the evidence actually shows.

In 26 healthy adults, a single 280 mg dose increased fMRI activity in brain regions tied to attention and short-term memory, but the memory improvement was not statistically significant (Rodriguez P et al., 2016, Radiology). A 2017 trial in bipolar disorder found that 195 mg a day reduced residual depression and anxiety more than a 15 mg comparison dose (Alda M et al., 2017). In cell and mouse studies, methylene blue reduced the build-up of tau, a protein linked to Alzheimer's disease (Congdon EE et al., 2012, Autophagy).

In cultured human cells, methylene blue delayed cell aging and extended how many times the cells could divide (Atamna H et al., 2008, FASEB Journal), and a later study found similar effects in skin cells (Xiong ZM et al., 2017, Scientific Reports). That's what drives research interest in aging.

We don't want to oversell this. Long-term human data on small daily servings doesn't exist yet. The research is real, and so are its limits.

Anyone buying methylene blue for off-label use should look for pharmaceutical-grade or USP-certified products from manufacturers who provide certificates of analysis. If you're wondering where to get it, see methylene blue near me: where to buy it safely. Full stop.

Psychiatric and Antidepressant Use

Methylene blue's psychiatric relevance comes mainly from the fact that it inhibits monoamine oxidase A, the same enzyme targeted by some of the earliest antidepressants (Ramsay RR et al., 2007, British Journal of Pharmacology).

The history here is underappreciated. Methylene blue's role as a monoamine oxidase inhibitor was identified decades after the original MAOIs, but it shares the same core pharmacology. In a 2017 randomised crossover trial in people with bipolar disorder, 195 mg a day reduced residual depression and anxiety more than a 15 mg comparison dose (Alda M et al., 2017, British Journal of Psychiatry). The trial was small, and this was off-label use under psychiatric care, not a supplement dose.

The monoamine oxidase inhibitor activity is also where the most serious psychiatric risk lives. Combining any monoamine oxidase inhibitor — including methylene blue — with SSRIs, SNRIs, or other serotonergic drugs can trigger serotonin syndrome. Serotonin syndrome isn't a mild reaction. It can be life-threatening — that's why the FDA has issued specific safety warnings about this interaction. If you're on any serotonergic antidepressant, you can't use methylene blue without medical supervision. Full stop.

Cognitive and Nootropic Use

Methylene blue is one of the more scientifically credible entries in the nootropic category — and the mechanisms behind that credibility are worth understanding properly. There isn't a single pathway at work here. There are at least three overlapping ones.

First, its mitochondrial electron transport role. Neurons are extraordinarily energy-demanding, and when that energy supply falters, cognitive performance suffers. By acting as an alternative electron shuttle in the mitochondrial electron transport chain — bypassing complexes I and III and donating electrons directly to cytochrome c — methylene blue may boost ATP production in neurons. That's especially relevant when mitochondrial function is already compromised by aging, stress, or environmental toxins.

Second, its effect on monoamine oxidase A raises levels of serotonin and norepinephrine, which are involved in mood and attention. Whether that changes day-to-day mental performance at supplement amounts hasn't been studied.

Third, its neuroprotective properties. In cell and mouse studies, methylene blue reduced tau build-up, a hallmark of Alzheimer's disease (Congdon EE et al., 2012, Autophagy). A related compound, LMTM, was tested in a phase 3 Alzheimer's trial and showed no benefit as an add-on treatment (Gauthier S et al., 2016, The Lancet).

Human neuroimaging has added some direct evidence. A University of Texas study found that a single dose increased fMRI activity in brain regions tied to attention and short-term memory in healthy adults, but the memory change was not statistically significant (Rodriguez P et al., 2016, Radiology).

Mitochondrial Energy and Metabolic Support

Methylene blue's mitochondrial effects don't stop at the brain — they extend to every cell that relies on oxidative phosphorylation for energy. In conditions of mitochondrial dysfunction — from aging, environmental toxins, or chronic disease — the electron transport chain often runs below capacity. Methylene blue's ability to bypass those bottlenecks and keep electron flow going represents a genuine cellular support mechanism, not marketing language.

In cultured human cells, methylene blue raised complex IV activity by about 30% and oxygen use by 37 to 70% (Atamna H et al., 2008, FASEB Journal), and in cell and animal models it kept energy production going when parts of the chain were blocked (Wen Y et al., 2011, Journal of Biological Chemistry). These are lab findings; they haven't been shown to reduce fatigue in people.

Anti-Aging and Cellular Protection

A 2017 study in Scientific Reports found that methylene blue slowed aging in cultured human skin cells, and on a lab-grown 3D skin model it improved hydration and thickness without causing irritation (Xiong ZM et al., 2017, Scientific Reports). Those results came from cells and skin models, not from people's skin.

The anti-aging mechanisms involve antioxidant activity, mitochondrial support, anti-inflammatory properties, and modulation of autophagy — the cellular self-cleaning process that declines with age. Reviews describe it as a candidate anti-aging drug (Xue H et al., 2021, Cells). It's promising, but it isn't settled science.

Antimicrobial Use: From Malaria to Photodynamic Therapy

Methylene blue's antimicrobial use predates antibiotics. It was the first synthetic drug used against malaria, and a 2018 review of 21 studies found it effective, especially combined with artemisinin-based drugs (Lu G et al., 2018, BMC Medicine).

Modern antimicrobial interest has shifted toward photodynamic therapy. Light-activated methylene blue generates reactive oxygen species that destroy bacterial cell membranes, viral capsids, and fungal cell walls — In dentistry, methylene blue photodynamic therapy is actively studied for treating periodontal disease and reducing bacterial loads in root canals. It's an area where the evidence is building, and where the antibiotic-resistance crisis makes alternatives genuinely urgent.

Why Is Methylene Blue Controversial?

With a resume this broad, it's fair to ask why methylene blue generates real controversy — and the answer isn't that the science is fake. The supplement market has outrun the evidence. Some marketing claims go well beyond what current research supports, presenting preliminary findings as established facts. That overclaiming has produced legitimate skepticism from the medical community, and that skepticism isn't wrong.

Self-dosing creates real risks. Serotonin syndrome from drug interactions, G6PD-related adverse reactions, and high-dose methemoglobinemia from using methylene blue at excessive levels — these are well-documented, serious risks that occur when people use it without understanding their own health status. They're not hypothetical dangers invented to scare people. They're documented in medical literature.

Quality control varies enormously — and this is where you have to be particularly careful. Industrial-grade methylene blue isn't made or tested for people, and it's sometimes sold cheaply online to people who don't realise what they're buying. Only pharmaceutical-grade methylene blue that meets the USP monograph should be consumed. The difference between grades isn't cosmetic. It's a safety issue.

Is methylene blue safe to take regularly? At low doses, from pharmaceutical-grade sources, without contraindicated medications, in people without G6PD deficiency — the safety profile appears acceptable. But "acceptable" doesn't mean "risk-free," and the honest answer depends entirely on your individual health status, your medications, and the quality of what you're taking.

How Do You Feel After Taking Methylene Blue?

There's no trial data on how small servings feel, and reports vary a lot. Some people describe clearer focus; many notice nothing obvious.

The thing that surprises first-time users most? The urine turns blue or green. It will. Methylene blue is a dye. The kidneys excrete it in its colored form. Completely normal and harmless, and it can last a day or two. The mouth and tongue may also stain blue temporarily after an oral solution. Same deal. And mild nausea is possible on an empty stomach — taking it with food generally solves that.

Who Should Not Take Methylene Blue?

People with G6PD deficiency. Full stop. The enzyme deficiency is more common than most people expect — particularly in individuals of African, Mediterranean, Middle Eastern, and Southeast Asian descent — and it turns methylene blue from a tool into a risk. Anyone from an at-risk population should test for G6PD status before considering methylene blue.

People on serotonergic medications. This is not a soft caution. The FDA-approved label carries a boxed warning: combined with SSRIs, SNRIs, MAOIs or opioids, methylene blue can cause serotonin syndrome, which can be fatal. It also lists bupropion, buspirone, clomipramine, mirtazapine, linezolid and dextromethorphan (FDA ProvayBlue label). Don't combine them outside direct medical supervision.

Pregnant and breastfeeding women should avoid it. People with kidney or liver impairment should only use it under medical supervision. Anyone with a known severe allergy to methylene blue or other thiazine dyes should avoid it entirely.

Why Grade and Purity Matter

Not all methylene blue is the same. Industrial and laboratory grades aren't made or tested for people to swallow. Canadian readers can also find pharmaceutical-grade options through a Canadian supplier such as Buy Methylene Blue Canada.

Pharmaceutical-grade or USP-grade methylene blue must meet the USP monograph: 97 to 103% methylene blue, with limits on impurities. That's the only grade appropriate for human consumption. Any supplement should come with a certificate of analysis from an independent laboratory confirming purity, concentration, and heavy metal levels. If the supplier won't provide one, walk away.

Concentration matters too. Pharmaceutical-grade solutions are typically formulated at 1% — 10 mg/mL. Accurate low-dose supplementation requires a calibrated measuring tool. A standard eyedropper without calibration is not precise enough for milligram-level dosing.

Conclusion

Methylene blue rewards serious attention. Its path from textile dye to biological stain to antimalarial drug to FDA-approved emergency medicine to modern nootropic candidate isn't a hype story. It's 150 years of genuine scientific utility revealing new dimensions in compound that was originally made to color fabric.

The evidence for its FDA-approved use is unassailable. The evidence for off-label uses in cognition, mood, and cellular health is promising and still growing. The contraindications and drug interactions are real and specific — not fine print.

So if you're exploring methylene blue: understand the contraindications first. Verify grade and purity of any product. Start low. And work with a healthcare provider who actually knows the compound. That's the foundation for using it responsibly.